肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

ONC201治疗胶质瘤的I / II期临床研究即将在日本开展

2020-04-02 Allan MedSci原创

胶质瘤ONC201多巴胺受体D2
关注

Oncoceutics制药公司宣布，ONC201已在临床前模型和多项正在进行的临床试验中证明了其抗胶质瘤的有效性和安全性。

Oncoceutics制药公司宣布，ONC201已在临床前模型和多项正在进行的临床试验中证明了其抗胶质瘤的有效性和安全性。ONC201是一种多巴胺受体D2（DRD2）的高度选择性拮抗剂，能够有效穿透血脑屏障。ONC201的DRD2拮抗作用与经过验证的抗癌途径有关，可导致癌细胞凋亡。Oncoceutics已使用ONC201在实体瘤中成功完成了一项I期临床研究，并且正在进行其他针对实体和血液恶性肿瘤的I / II和II期临床计划。

Oncoceutics首席运营官Lee Schalop表示：“随着我们将ONC201的开发范围扩展到美国以外的重要市场，ONC201将为日本神经胶质瘤患者提供一种新的治疗选择”。胶质瘤占脑实质内原发性肿瘤的绝大多数。胶质瘤是指组织学特征与正常胶质细胞（即星形胶质细胞、少突胶质细胞和室管膜细胞）相似的肿瘤。每种胶质瘤的生物学侵袭性都存在很大的变化范围。

 

原始出处：

https://www.firstwordpharma.com/node/1712523?tsid=4

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1653008, encodeId=3272165300810, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue May 05 00:36:23 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650001, encodeId=c41b165000173, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Mon Aug 03 13:36:23 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808438, encodeId=f9fb80843855, content=期待国内有临床计划, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58315410721, createdName=ms2000002079471213, createdTime=Thu Aug 13 14:33:37 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294538, encodeId=e25712945381f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Apr 04 11:36:23 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524795, encodeId=21a01524e9540, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat Apr 04 11:36:23 CST 2020, time=2020-04-04, status=1, ipAttribution=)]
    2020-05-05 医生2402

    #I期临床#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1653008, encodeId=3272165300810, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue May 05 00:36:23 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650001, encodeId=c41b165000173, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Mon Aug 03 13:36:23 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808438, encodeId=f9fb80843855, content=期待国内有临床计划, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58315410721, createdName=ms2000002079471213, createdTime=Thu Aug 13 14:33:37 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294538, encodeId=e25712945381f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Apr 04 11:36:23 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524795, encodeId=21a01524e9540, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat Apr 04 11:36:23 CST 2020, time=2020-04-04, status=1, ipAttribution=)]
    2020-08-03 huiwelcome

    #II期临床研究#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1653008, encodeId=3272165300810, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue May 05 00:36:23 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650001, encodeId=c41b165000173, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Mon Aug 03 13:36:23 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808438, encodeId=f9fb80843855, content=期待国内有临床计划, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58315410721, createdName=ms2000002079471213, createdTime=Thu Aug 13 14:33:37 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294538, encodeId=e25712945381f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Apr 04 11:36:23 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524795, encodeId=21a01524e9540, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat Apr 04 11:36:23 CST 2020, time=2020-04-04, status=1, ipAttribution=)]
    2020-08-13 ms2000002079471213

    期待国内有临床计划

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1653008, encodeId=3272165300810, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue May 05 00:36:23 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650001, encodeId=c41b165000173, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Mon Aug 03 13:36:23 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808438, encodeId=f9fb80843855, content=期待国内有临床计划, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58315410721, createdName=ms2000002079471213, createdTime=Thu Aug 13 14:33:37 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294538, encodeId=e25712945381f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Apr 04 11:36:23 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524795, encodeId=21a01524e9540, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat Apr 04 11:36:23 CST 2020, time=2020-04-04, status=1, ipAttribution=)]
    2020-04-04 chentianping

    #日本#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1653008, encodeId=3272165300810, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue May 05 00:36:23 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650001, encodeId=c41b165000173, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Mon Aug 03 13:36:23 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808438, encodeId=f9fb80843855, content=期待国内有临床计划, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58315410721, createdName=ms2000002079471213, createdTime=Thu Aug 13 14:33:37 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294538, encodeId=e25712945381f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Apr 04 11:36:23 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524795, encodeId=21a01524e9540, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat Apr 04 11:36:23 CST 2020, time=2020-04-04, status=1, ipAttribution=)]
    2020-04-04 guihongzh

    #II期临床#

    0

相关资讯

疫路有我，阔然开朗：胶质瘤、脑转移瘤在线公益答疑

2020年3月14日，第一期“阔然专栏”在线直播栏目邀请复旦大学附属华山医院秦智勇教授、盛晓芳教授、梁晓华教授、庄冬晓教授和陈宏教授、徐州医科大学附属医院肿瘤中心章龙珍教授、复旦大学附属肿瘤医院曹依群

Nat Cell Bio：利用CRISPR技术精准修正胶质瘤致癌基因突变

研究人员使用腺相关病毒（Adeno-associated virus， AAV）作为载体表达拥有腺嘌呤脱氨酶活性的空肠弯曲菌（Campylobacter jejuni）Cas9融合蛋白以及对应的单向导RNA（sgRNA），实现精准修正胶质瘤细胞端粒酶基因启动子区域的致癌突变。

Radiology：对于高级别胶质瘤患者的治疗，手术期间做个MRI值不值？

背景：有研究证实手术期间MRI能够提高高级别胶质瘤瘤体切除的效果。然而，就作者所知，对于手术期间MRI的性价比尚无评价。本研究旨在建立评估手术期间MRI 在治疗高级别性价比的临床决策模型。

Sci transl med：IL-12基因疗法治疗复发性高级别胶质瘤的安全性和疗效

人白介素-12（hIL-12）是一种具有抗癌活性的细胞因子，但其系统应用受到毒性炎症反应的限制。研究人员对用一种口服激活剂来调控hIL-12基因的转录的安全性和生物效率进行评估。本研究为多中心的1期剂量递增性试验，共31位进行复发性高级别胶质瘤再切除手术的患者接受试验治疗。手术当天，向切除腔壁注射固定剂量的hIL-12载体（Ad-RTS-hIL-12）。hIL-12的口服激活剂veledimex

陈忠平教授：2019年胶质瘤诊疗进展盘点

作为最常见的原发性颅内恶性肿瘤，胶质瘤是神经肿瘤领域最重要的瘤种，也是一个巨大的挑战。恶性胶质瘤约占所有胶质瘤的70%，治疗效果差，5年生存率仅在10%上下。近年，得益于基因组学、表观遗传学及肿瘤免疫学研究的深入，胶质瘤分子病理诊断与疗效评估以及新药物、新疗法的开发等方面均有颇多进展，以下对2019年度的诊疗进展进行盘点。诊断进展继IDH突变、1p19q共缺失及TERT突变等被引入WHO中枢神经系

老年女性头晕1年余，加重1月.....

老年女性头晕1年余，加重1月.....

拓展阅读

European Radiology：协调病灶位置分析在脑胶质瘤放射组学诊断中的应用

基于感兴趣区域 (ROI) 的影像学分析是探索胶质瘤病理学特征的经典策略，可通过定量测量区域物质的影像学特征。初步的ROI分析直接测量了胶质瘤内的信号强度、扩散、灌注或代谢参数的平均值。

结合NGS和传统诊断结果，可实现3-4级胶质瘤的诊断更精准，并提供潜在靶向治疗

本研究旨在确定将NGS结果与传统诊断数据相结合对临床诊断和患者管理的影响。

为什么胶质瘤患者需要检测CDKN2A/B缺失变异？

胶质瘤是最常见的原发颅内恶性肿瘤，有较高的死亡率和致残率。然而，不同胶质瘤患者的总生存期差异显著。临床上，根据患者的免疫表型、血管增生、核分裂象、基因变异等因素，对患者进行预后分层。

胶质瘤WHO分类标准、影像诊断要点、RANO治疗效果评估标准、分子表型一网打尽

胶质瘤WHO分类标准、影像诊断要点、RANO治疗效果评估标准、分子表型，一篇帮您全搞定，建议收藏起来慢慢看。

European Radiology：胶质瘤侵犯海马时会有何影像学改变！

作为研究最彻底的大脑结构之一，海马由许多不同的、相互作用的亚区组成，形成了一个异质性的复杂结构。

European Radiology：灌注加权成像在成人弥漫性胶质瘤诊断中的应用

目前一些研究表明，根据2016年的标准，分子特征分析会影响胶质瘤的预后。例如，有IDH突变的胶质瘤患者比有野生型IDH的患者生存时间更长。